LegoChem Biosciences, Inc.
http://www.legochembio.com/eng/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From LegoChem Biosciences, Inc.
Korean Vs Global Biopharma M&A Trends: How Different Are They?
A number of recent significant transactions in the South Korean biopharma space indicate some emerging trends as the sector develops and expands internationally. Scrip takes a look at the over-arching themes in M&A activity over the past few years and how these may differ from those being observed globally.
J&J Has An Appetite For Pharma M&A, But Knows What It Likes
CEO Joaquin Duato said J&J is agnostic on size when it comes to business development but has generally found more value creation in earlier-stage deals.
ADC Specialist LegoChem Takes Orion’s Hand As Long-Term Partner
Korean confectionery group Orion has become the biggest shareholder in compatriot ADC specialist LegoChem Biosciences, in a decisive step to move into the biotech sector as a new growth engine. For LegoChem, the alliance provides a friendly strategic partner and should enable a boost in R&D spending as it seeks to aggressively progress clinical trials and become a global player.
J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout
CEO Joaquin Duato told the J.P. Morgan Healthcare Conference that the drug maker hopes the $2bn acquisition can make one of its lead candidates, ARX517, the first PSMA-directed ADC for prostate cancer.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice